As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Jim Lebenthal of Cerity Partners picked Vertex Pharmaceuticals Incorporated VRTX. Adding support to his choice, the company, on Jan. 31, secured FDA approval for JOURNAVX, a non-opioid oral pain ...

LONDON, January 31, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sionna Therapeutics on Thursday raised $191 million in an initial public offering that will fund its plan to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis franchise. The company sold ...

Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge. It has now established its global headquarters on Fan Pier in South Boston’s Seaport District ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.